FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3
- PMID: 15147956
- DOI: 10.1016/j.bbrc.2004.04.110
FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3
Abstract
Proliferation, differentiation, and survival of hematopoietic cells are regulated by cytokines, acting through specific receptors. FLT3 ligand (FL) is one of the most important cytokines for regulation of the hematopoietic system, and its receptor FLT3 is expressed on both stem cells and progenitors. Regulation of Forkhead transcription factors has been described as an important mechanism to control apoptosis and cell cycle progression in hematopoietic progenitors. Here we report that FL induces AKT/PKB activation, which in turn phosphorylates and thereby inactivates the Forkhead protein FoxO3 in the progenitor cell line FDC-P1 stably expressing murine FLT3 receptor. Phosphorylation of AKT and FoxO3 was blocked by the PI-3 kinase inhibitor LY294002 but not by the MAP kinase inhibitor PD98059. Expression of a mutated FoxO3, in which all three inhibitory phosphorylation sites were mutated to alanine, led to rapid increase of apoptotic cells in the presence of FL. These results suggest that FL-induced regulation of apoptosis is executed by FoxO3.
Similar articles
-
Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand.Exp Hematol. 2003 Apr;31(4):316-23. doi: 10.1016/s0301-472x(03)00002-x. Exp Hematol. 2003. PMID: 12691919
-
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.Oncogene. 2004 Apr 22;23(19):3338-49. doi: 10.1038/sj.onc.1207456. Oncogene. 2004. PMID: 14981546
-
FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity.J Cell Biol. 2002 Feb 4;156(3):531-42. doi: 10.1083/jcb.200108084. Epub 2002 Jan 28. J Cell Biol. 2002. PMID: 11815629 Free PMC article.
-
Therapeutic Consequences of Targeting the IGF-1/PI3K/AKT/FOXO3 Axis in Sarcopenia: A Narrative Review.Cells. 2023 Dec 7;12(24):2787. doi: 10.3390/cells12242787. Cells. 2023. PMID: 38132107 Free PMC article. Review.
-
Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs.Leukemia. 1999 Aug;13(8):1109-66. doi: 10.1038/sj.leu.2401493. Leukemia. 1999. PMID: 10450743 Review.
Cited by
-
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.Oncol Rev. 2012 Apr 17;6(1):e8. doi: 10.4081/oncol.2012.e8. eCollection 2012 Mar 5. Oncol Rev. 2012. PMID: 25992210 Free PMC article. Review.
-
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.Cancer Biol Ther. 2011 Mar 15;11(6):552-8. doi: 10.4161/cbt.11.6.14675. Epub 2011 Mar 15. Cancer Biol Ther. 2011. PMID: 21282974 Free PMC article.
-
Interferon gamma has dual potential in inhibiting or promoting survival and growth of hematopoietic progenitors: interactions with stromal cell-derived factor 1.Int J Hematol. 2006 Aug;84(2):143-50. doi: 10.1532/IJH97.A30606. Int J Hematol. 2006. PMID: 16926136
-
Flt3 Signaling in B Lymphocyte Development and Humoral Immunity.Int J Mol Sci. 2022 Jun 30;23(13):7289. doi: 10.3390/ijms23137289. Int J Mol Sci. 2022. PMID: 35806293 Free PMC article. Review.
-
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Blood. 2008 Apr 1;111(7):3723-34. doi: 10.1182/blood-2007-09-114454. Epub 2008 Jan 9. Blood. 2008. PMID: 18184863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous